Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-03-22
1997-12-16
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424487, 514 4, A61K 3828, A61K 4730
Patent
active
056985150
ABSTRACT:
An insulin-containing polymer composition intended for the oral administration of insulin, which comprises a hydrophilic polymer modified with an inhibitor of proteolytic enzyme, insulin and water, wherein the inhibitor of proteolytic enzymes is ovomucoid isolated from duck or turkey egg whites.
REFERENCES:
patent: 4238480 (1980-12-01), Sawyer
patent: 4579730 (1986-04-01), Kidron et al.
patent: 4795436 (1989-01-01), Robinson
patent: 4849227 (1989-07-01), Cho
patent: 5049545 (1991-09-01), Lobermann et al.
patent: 5206219 (1993-04-01), Desai
patent: 5340731 (1994-08-01), Kilburn et al.
patent: 5438040 (1995-08-01), Ekwuribe
patent: 5563056 (1996-10-01), Swan et al.
"Thermally Reversible Hydrogels Containing Biologically Active Species", Hoffman, Polymers in Medicine III, Elsevier Science Publishers B.V., Amsterdam, 1988, pp. 161-167.
"The Acetylation of Insulin", Lindsay et al, Biochem. J. 121 (1971), p. 737.
"Monosubstituted 2,2-Dimethyl-3-Formyl-L-Thiazolidine-4-Carbonyl Insulins", Lindsay et al, Eur. J. Biochem. 15 (1970) p. 547.
"Intramolecular Cross-Linked Insulin", D.G. Lindsay, Mar. 1971, Febs Lett., vol. 21, No. 1, p. 105.
"Improvement of Large Intestinal Absorption of Insulin by Chemical Modification with Palmitic Acid in Rats", Hashizume et al, J. Pharm. Pharmacol. 1992, 44:557-558.
"Trials of Lipid Modification of Peptide Hormones for Intestinal Delivery", Muranishi et al, Journal of Controlled Release, 19 (1992), PP. 179-180.
"Hypoglycemic Effect of Intestinally Administered Monosaccharide-Modified Insulin Derivatives in Rats", Haga et al, Chem. Pharm. Bull. 39(7) (1990), pp. 1983 & 1986.
"Effect of Trypsin Inhibitor on Passage of Insulin Across the Intestinal Barrier", Science, 127, 1988, pp. 1115-1116.
Seals, J.R. Evidence That Insulin Activates an Intrinsic Plasma Membrane. J. Biol. Chem. Jul. 25, 1980. vol. 255, No. 14, pp. 6529-6531.
Braganza, V.J. et al. Tryptase from Rat Skin. Biochemistry. 1991. vol. 30, No. 20, pp. 4997-5007.
Morishita, I. et al. Hypoglycemic Effect of Novel Oral Microspheres of Insulin. Int. J. Pharm. 1992 pp. 9-16.
Greenley, R.Z., et al. "Polymer Matrices for Oral Delivery". Polymer Preprints, vol. 31, No. 2 (Aug. 1990, Papers Presented at the Washington, D.C. Meeting, American Chemical Society, pp. 182-183.
Saffran, Murray, et al., "Biodegradable Azopolymer Coating . . . " Biochemical Society Transactions, vol. 18 (1990), pp. 752-754.
Damge, C., et al., "Nanocapsules as Carriers for Oral Peptide Delivery". Journal of Controlled Release, vol. 13 (1990), pp. 233-239.
Ametov Alexandr Sergeevich
Knyazhev Vladimir Alexnadrovich
Plate Nikolai Alfredovich
Staroseltseva Ljudmila Konstantinovna
Valuev Lev Ivanovich
Institut Neftekhimicheskogo Sinteza Imeni A.V.Topchieva Rossiisk
Russel Jeffrey E.
Shust, Esq. Nestor W.
LandOfFree
Insulin-containing polymer composition for oral administration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Insulin-containing polymer composition for oral administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin-containing polymer composition for oral administration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-205946